The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- Patients now shop for doctors like consumers, and the bar just got higher (Medical Economics)
- AI in GI cancer care: From recognition to clinical value (ESMO)
- Could the Gut Microbiome Improve Colorectal Cancer Screening? (Technology Networks)
- DDW Expert Picks: Endoscopists’ Peripheral Gaze, Antibiotics for Cholangitis, and More
- The loopholes PE built to buy physicians are starting to crack (Becker’s Healthcare)
- Barrett Esophagus May Strike Decades Before Official Diagnosis (Medscape)
- A blood-based test for detection of advanced adenomas and colorectal cancer (DENEB): a multicentre diagnostic accuracy study (The Lancet Gastroenterology & Hepatology)
- AI can analyze your poop. Should it? (Business Insider)
